최일규
Choi, Il-Kyu학력
- 2006 ~ 2012연세대학교 박사
- 2004 ~ 2006연세대학교 석사
- 1998 ~ 2004한국외국어대학교 학사
경력
- 2020 ~ 2021Dana-Farber Cancer Institute/Harvard Medical School / Instructor
- 2013 ~ 2019Dana-Farber Cancer Institute/Harvard Medical School / Postdoctoral Fellow
- 2012 ~ 2013Hanyang University / Postdoctoral Fellow
수상실적
- 2020The 2019 Barr Fellow of Claudia Adams Barr Program
- 2015Best Poster Award
- 2011KSGCT Poster Prize
- 2009Poster Award for Excellence
- 2008Poster Award for Excellence
연구실 소개
- Lab of T-cell Biology and Immunotherapy
-
Our laboratory aims to understand the fundamental biology of T cells in health and disease, and translate the discoveries into novel immunotherapeutic approaches for intractable diseases. With our own unique model systems, we currently focus on the following research projects which lie at the intersection of immunology, virology and cancer treatment. This research program, if successful, will place our lab in a unique position to open new avenues of research in the human virobiota and CD4 CTL biology, and lead to the development of innovative cancer immunotherapies.
Research Interests
Related Keyword
- "IL2-mediated modulation of small extracellular vesicles secretion and PD-L1 expression: a novel perspective for neutralizing immune suppression within cancer cells", Noh, Soojeong. (2024-12). IL2-mediated modulation of small extracellular vesicles secretion and PD-L1 expression: a novel perspective for neutralizing immune suppression within cancer cells. Cancer Communications, 44(12), 1422–1426. doi: 10.1002/cac2.12623
- "CD4+ cytotoxic T cells: an emerging effector arm of anti-tumor immunity", Jeong, Seongmin. (2023-02). CD4+ cytotoxic T cells: an emerging effector arm of anti-tumor immunity. BMB Reports, 56(3), 140–144. doi: 10.5483/BMBRep.2023-0014
- "Does delayed EBV infection contribute to rising childhood cancers?", Zhang, Baochun. (2022-12). Does delayed EBV infection contribute to rising childhood cancers? Trends in Immunology, 43(12), 956–958. doi: 10.1016/j.it.2022.09.009
- "Facts and Hopes in the Relationship of EBV with Cancer Immunity and Immunotherapy", Zhang, Baochun. (2022-10). Facts and Hopes in the Relationship of EBV with Cancer Immunity and Immunotherapy. Clinical Cancer Research, 28(20), 4363–4369. doi: 10.1158/1078-0432.CCR-21-3408
- "Recent advances in single-cell metabolomics using mass spectrometry: emerging challenges and future perspectives", Alam, Rafiqul. Recent advances in single-cell metabolomics using mass spectrometry: emerging challenges and future perspectives. Applied Spectroscopy Reviews. doi: 10.1080/05704928.2025.2483996
- "CD4 Cytotoxic T Cells Promote Antitumor Immunity in Multiple Myeloma", Kim, Sojeong. (2024-12-08). CD4 Cytotoxic T Cells Promote Antitumor Immunity in Multiple Myeloma. 66th Annual Meeting of the American Society of Hematology (ASH), 668–669. doi: 10.1182/blood-2024-199396
- "Cd70 Deficiency Impairs CD4+and CD8+T-Cell Immune Surveillance in Bcl6-Driven Diffuse Large B-Cell Lymphomas", Mandato, Elisa. (2023-11-02). Cd70 Deficiency Impairs CD4+and CD8+T-Cell Immune Surveillance in Bcl6-Driven Diffuse Large B-Cell Lymphomas. 65th Annual Meeting of the American-Society-of-Hematology (ASH), 1624–1625. doi: 10.1182/blood-2023-186297
연구분야
미래유망 신기술(6T)
-
20000. BT(생명공학기술)
-
20200. 보건의료 관련응용
20212. 난치성 질환 치료기술
-
-
30000. ST(우주항공기술)
-
30300. 나노 바이오 보건
30312. 의약 약물전달 시스템
-
국가과학기술표준분류
-
LC. 보건의료
-
LC01. 의생명과학
LC0106. 면역학
-
-
LA. 생명과학
-
LA07. 융합바이오
LA0703. 나노바이오소재
-
-
LC. 보건의료
-
LC02. 임상의학
LC0205. 혈액/종양학
-
-
LC. 보건의료
-
LC03. 신약·의약품개발
LC0309. 약물전달시스템
-
-
LC. 보건의료
-
LC03. 신약·의약품개발
LC0316. 백신
-
12대 국가전략기술 분야
-
첨단바이오
유전자·세포 치료